| Dr Yannek Isaac Leiderman, MD, PHD | |
|
1855 W Taylor St # Mc648, Uic Dept Of Ophthalmology And Visual Sciences, Chicago, IL 60612-7242 | |
| (312) 413-4999 | |
| Not Available |
| Full Name | Dr Yannek Isaac Leiderman |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 1855 W Taylor St # Mc648, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164586616 | NPI | - | NPPES |
| 30209380 | Medicaid | NH | |
| 1962590232 | Other | MA | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 235488 (Massachusetts) | Primary |
| 207W00000X | Ophthalmology | 224712 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Illinois Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Board Of Trustees Of The University Of Illinois | 3072422716 | 929 |
News Archive
A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
By now, Americans everywhere are receiving premium increases and new policy choices when it comes to healthcare. Subscribers' rates are increasing and companies are making decisions about what they plan to do with the rising costs heading their way, says Frank N. Darras, the nation's top insurance lawyer.
› Verified 5 days ago
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
By now, Americans everywhere are receiving premium increases and new policy choices when it comes to healthcare. Subscribers' rates are increasing and companies are making decisions about what they plan to do with the rising costs heading their way, says Frank N. Darras, the nation's top insurance lawyer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yannek Isaac Leiderman, MD, PHD 1855 W Taylor St # Mc648, Uic Dept Of Ophthalmology And Visual Sciences, Chicago, IL 60612-7242 Ph: (312) 413-4999 | Dr Yannek Isaac Leiderman, MD, PHD 1855 W Taylor St # Mc648, Uic Dept Of Ophthalmology And Visual Sciences, Chicago, IL 60612-7242 Ph: (312) 413-4999 |
News Archive
A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study.
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
By now, Americans everywhere are receiving premium increases and new policy choices when it comes to healthcare. Subscribers' rates are increasing and companies are making decisions about what they plan to do with the rising costs heading their way, says Frank N. Darras, the nation's top insurance lawyer.
› Verified 5 days ago
Paul Owen Phelps, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2001 N Halsted St Ste 200, Chicago, IL 60614 Phone: 312-888-5754 Fax: 833-989-2458 | |
Dr. David Alan Ramirez Jr., MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 225 E Chicago Ave # 70, Chicago, IL 60611 Phone: 312-227-6180 | |
Curtis James Heisel, Ophthalmology Medicare: Medicare Enrolled Practice Location: 251 E Huron St, Chicago, IL 60611 Phone: 312-227-4000 | |
Dr. John B Bello, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7447 W Talcott Ave, Suite 406, Chicago, IL 60631 Phone: 773-775-9755 Fax: 773-775-4306 | |
Adrienne Berman, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1740 W Taylor St, Chicago, IL 60612 Phone: 866-600-2273 | |
Jhansi Raju, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3700 W 26th St, Chicago, IL 60623 Phone: 773-542-5203 Fax: 773-542-5841 | |
Catherine Jane Thomas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 1520, Chicago, IL 60611 Phone: 312-695-8150 Fax: 312-503-8152 |